度普利尤单抗在慢性鼻窦炎伴鼻息肉治疗中的研究进展

慢性鼻窦炎(CRS)是一种常见的鼻窦黏膜炎症性疾病,复杂的发生机制造就了CRS的高度异质性,部分患者无法从目前标准的药物治疗和手术中得到缓解。CRS具有不同的炎症内型和临床表型,慢性鼻窦炎伴鼻息肉(CRSwNP)一直是治疗难点,其症状相对较重还常合并哮喘,易对常规药物和手术的疗效不佳并伴有较高的复发风险。近年来,度普利尤单抗(dupilumab)在成人顽固性CRSwNP中疗效显著,其通过阻断Ⅱ型炎症中关键驱动因子IL-4和IL-13的信号传导,达到治疗作用。目前度普利尤单抗对国人CRSwNP治疗研究尚无报道。本文将对度普利尤单抗治疗CRSwNP的研究进展进行综述,以期为其在CRSwNP中的进一步应用研究提供参考。

Research advances of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps

Chronic rhinosinusitis(CRS)is a common inflammatory disease of the paranasal sinus mucosa. Complex mechanisms lead to a strongly heterogeneous CRS, and some patients do not find relief using the current standard drug treatment and surgery. CRS has different inflammatory endotypes and clinical phenotypes; CRS with nasal polyps(CRSwNP)has always been difficult to treat, as its symptoms are relatively severe and often complicated by asthma. It is often unresponsive to conventional drugs and surgery and has a high risk of reoccurring. In recent years, dupilumab has been found to be effective in adult intractable CRSwNP by blocking the signal transduction of interleukin(IL)-4 and IL-13, which are the key driving factors in type II inflammation. Currently, the study of dupilumab in the treatment of CRSwNP in China has not been reported. This article reviews the progress achieved in the research of dupilumab in the treatment of CRSwNP, to provide a reference for its further application and research in treating CRSwNP.